

15 October 2020

ASX Announcement
ASX Companies Announcements Platform

Notice under Section 708AA of the Corporations Act 2001 (Cth)

Actinogen Medical Limited ACN 086 778 476 (**Actinogen or the Company**), (ASX code: **ACW**) today announced a non-renounceable entitlement offer to eligible shareholders on the basis of 1 new share (**New Share**) for every 5 shares held as at the Record Date at an Issue Price of 2.2 cents to raise up to approximately \$4.91 million before costs by the issue of approximately 223,246,264 New Shares (**Entitlement Offer**).

Eligible shareholders are those shareholders who are, as at 7.00pm AEDT time on the Record Date (being Tuesday, 20 October 2020), registered with a registered address situated in Australia and New Zealand (**Eligible Shareholders**).

In accordance with section 708AA(2)(f) of the *Corporations Act 2001 (Cth)* (**the Act**), the Company gives notice that:

- (a) the New Shares will be offered for issue without disclosure to investors under Part 6D.2 of the Act;
- (b) this notice is given by the Company under section 708AA(2)(f) of the Act;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (ii) section 674 of the Act;
- (d) as at the date of this notice, there is no information:
 - (i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules of ASX; and
 - (ii) that investors and their professional advisers would reasonably require, and would reasonably expect to find in a disclosure document, for the purpose of making an informed assessment of:
 - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
 - (B) the rights and liabilities attaching to the New Shares;
- (e) the potential effect that the issue of the New Shares under the Entitlement Offer will have on the control of the Company and the consequences of that will depend on a number of factors including specific investor demand. Assuming that all the shares offered under the Entitlement Offer are subscribed, the capital structure before the Entitlement Offer and the potential structure after the Entitlement Offer is set out below:

Issued Shares	Shares
Total issued capital of the Company as at the Record Date	1,116,231,320
Number of Shares offered under the Entitlement Offer (assuming maximum number of Shares are issued under the Entitlement Offer)	223,246,264
Number of Shares to be issued under the Placement as announced on 15 October 2020	272,727,273
Total Issued Capital of the Company at completion of the Entitlement Offer	1,612,204,857

Investors should note the following:

- if particular Eligible Shareholders do not take up all of their entitlements under the offer, the share interests of those Shareholders will be diluted;
- the proportional interests of Shareholders with registered addresses outside Australia and New Zealand will be diluted because those Shareholders are not entitled to participate in the Entitlement Offer; and
- should the Company's major Shareholders subscribe for their full entitlement under the Entitlement Offer, there will not be any material impact on the control of the Company following the issue of Shares under the Entitlement Offer.

Further details about the Entitlement Offer were announced on 15 October 2020.

For further information, please view our website (www.actinogen.com.au) or contact the Company Secretary on +61 409 328 199.

The release of this announcement was authorised by the Board of Actinogen.

Yours faithfully




Peter Webse
Company Secretary

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Investor Enquiries

Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com